Literature DB >> 27451955

Pancreatic cancer: Dodging immunosuppression.

Sarah Seton-Rogers.   

Abstract

Entities:  

Year:  2016        PMID： 27451955     DOI： 10.1038/nrc.2016.80

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

1.  Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo
Journal:  Nat Med       Date:  2016-07-04       Impact factor: 53.440
  1 in total
  4 in total

1.  Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.

Authors:  Lei Miao; Jingjing Li; Qi Liu; Richard Feng; Manisit Das; C Michael Lin; Tyler J Goodwin; Oleksandra Dorosheva; Rihe Liu; Leaf Huang
Journal:  ACS Nano       Date:  2017-08-28       Impact factor: 15.881

Review 2.  Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment.

Authors:  Shuangshuang Lu; Tasqeen Ahmed; Pan Du; Yaohe Wang
Journal:  Int J Mol Sci       Date:  2017-06-05       Impact factor: 5.923

Review 3.  Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?

Authors:  Thomas C Wirth; Florian Kühnel
Journal:  Front Immunol       Date:  2017-12-19       Impact factor: 7.561

4.  The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.

Authors:  Fang Xie; Mei Huang; Xiansheng Lin; Chenhai Liu; Zhen Liu; Futao Meng; Chao Wang; Qiang Huang
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.